Validating survivin as a cancer therapeutic target.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 12509766.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Acquisition of the ability to evade cellular suicide, or apoptosis, is one of the master switches that contributes to cellular transformation and, ultimately, to invasive cancer. Much has been learned about the molecular organization of apoptotic pathways and their regulators, but the identification and validation of translational targets for apoptosis-based cancer therapy has posed a great challenge. Survivin is an attractive candidate for cancer therapy, so what is its potential applicability in the clinic?
Medical subject headings
- Cysteine Proteinase Inhibitors
- Microtubule-Associated Proteins
- Neoplasms